CLOs on the Move

Well and Company

www.wellandcompany.com

 
Well & Company™ is igniting a self care revolution, offering its community members a powerful opportunity to share daily strategies that confront significant health and lifestyle challenges including aging, weight gain, fatigue, sleeplessness, stress, and loneliness. We “Embrace the Day™,” through social selling with our engaging content, innovative products and inspired community.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Thornhill Research

Thornhill Research Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Occupational Environmental Health Solutions

Occupational Environmental Health Solutions is a Chatham, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vermont Nurse Alliance of Vermont and New Hampshire

Visiting Nurse and Hospice for Vermont and New Hampshire (VNH) is a non‐profit organization that has provided home health and hospice care services in Vermont and New Hampshire since 1907. The agency is dedicated to delivering outstanding home- and community-based health and hospice services that enrich the lives of the people they serve. VNH makes home visits to people of all ages and all stages of life – regardless of ability to pay – and also provides communities with education and wellness programs. Currently, VNH serves more than 150 towns in Vermont and New Hampshire and covers 4,000 square miles. VNH caregivers provide services for more than 5,000 people each year and makes more than 150,000 home visits to people of all ages and at all stages of life.

Kinetik Medical Devices Inc

Kinetik Medical Devices Inc is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.